U.S. flag

An official website of the United States government

NM_001018115.3(FANCD2):c.708dup (p.Glu237fs) AND Fanconi anemia complementation group D2

Germline classification:
Likely pathogenic (1 submission)
Last evaluated:
Feb 19, 2024
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV004576548.1

Allele description [Variation Report for NM_001018115.3(FANCD2):c.708dup (p.Glu237fs)]

NM_001018115.3(FANCD2):c.708dup (p.Glu237fs)

Genes:
LOC107303338:3p25 FANCD2 Alu-mediated recombination region [Gene]
FANCD2:FA complementation group D2 [Gene - OMIM - HGNC]
Variant type:
Duplication
Cytogenetic location:
3p25.3
Genomic location:
Preferred name:
NM_001018115.3(FANCD2):c.708dup (p.Glu237fs)
HGVS:
  • NC_000003.12:g.10041635dup
  • NG_007311.1:g.20207dup
  • NG_046754.1:g.10789dup
  • NM_001018115.3:c.708dupMANE SELECT
  • NM_001319984.2:c.708dup
  • NM_001374253.1:c.708dup
  • NM_001374254.1:c.708dup
  • NM_033084.6:c.708dup
  • NP_001018125.1:p.Glu237Argfs
  • NP_001018125.1:p.Glu237fs
  • NP_001306913.1:p.Glu237fs
  • NP_001361182.1:p.Glu237fs
  • NP_001361183.1:p.Glu237fs
  • NP_149075.2:p.Glu237Argfs
  • NP_149075.2:p.Glu237fs
  • LRG_306t1:c.708dup
  • LRG_306t2:c.708dup
  • LRG_306:g.20207dup
  • LRG_306p1:p.Glu237Argfs
  • LRG_306p2:p.Glu237Argfs
  • NC_000003.11:g.10083319dup
  • NM_001018115.1:c.708dup
  • NM_033084.3:c.708dup
Protein change:
E237fs
Molecular consequence:
  • NM_001018115.3:c.708dup - frameshift variant - [Sequence Ontology: SO:0001589]
  • NM_001319984.2:c.708dup - frameshift variant - [Sequence Ontology: SO:0001589]
  • NM_001374253.1:c.708dup - frameshift variant - [Sequence Ontology: SO:0001589]
  • NM_001374254.1:c.708dup - frameshift variant - [Sequence Ontology: SO:0001589]
  • NM_033084.6:c.708dup - frameshift variant - [Sequence Ontology: SO:0001589]

Condition(s)

Name:
Fanconi anemia complementation group D2
Synonyms:
FANCONI PANCYTOPENIA, TYPE 4; FANCONI ANEMIA, COMPLEMENTATION GROUP D
Identifiers:
MONDO: MONDO:0009214; MedGen: C3160738; Orphanet: 84; OMIM: 227646

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV005057633Baylor Genetics
criteria provided, single submitter

(ACMG Guidelines, 2015)		Likely pathogenic
(Feb 19, 2024) 		unknownclinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedunknownunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee.

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]
PMID:
25741868
PMCID:
PMC4544753

Details of each submission

From Baylor Genetics, SCV005057633.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Jun 17, 2024